Kristin Wynholds - Apr 1, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Product Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Stock symbol
BTTX
Transactions as of
Apr 1, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:45 PM
Previous filing
Nov 1, 2021
Next filing
Dec 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +117K $0.00 117K Apr 1, 2022 Common Stock 117K $1.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.